Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) — The "Narcolepsy Drugs Market – Global Industry Analysis (2018 – 2020) – Growth Trends and Market Forecast (2021 – 2026)" report has been added to ResearchAndMarkets.com's offering.
This report indicates that the global narcolepsy drugs market will reach a valuation of US$6,588 Mn by 2025 from US$3,875.1 Mn in 2021.
The demand for these drugs will be pushed up due to the improving diagnostics around the condition, which renders the excessively sleepy during the daytime. Although a relatively rare disorder, analysts predict that the demand for the same will be driven by higher awareness about the medical condition. Its symptoms such as cataplexy and hallucinations, which can be life-threatening have prompted players to invest in the research and development of drugs. Between the forecast years of 2021 and 2025, the global narcolepsy drugs market is expected to surge at a CAGR of 11.2%, indicating steady growth.
Conclusive Diagnosis of Narcolepsy that Manifests with Cataplexy to Lead Global Narcolepsy Drugs Market
The COVID-19 pandemic brought with it a range of sleep disorders, highlighting the need to treat them to better daytime wakefulness and productivity. Narcolepsy with cataplexy or type 1 narcolepsy is expected to hold a market share of 68.8% in 2021. As the combination of two ensure a conclusive diagnosis, the segment is expected to lead the way in the global narcolepsy drugs market. The report indicates that despite receiving treatment for narcolepsy, patients can develop cataplexy at later stages. According to the National Sleep Foundation, more than 60% of narcoleptic patients suffer from type 1 narcolepsy. Thus, the segment is expected to dominate the global market during the forecast period.
Sodium Oxybate to Dominate as it Remains Critical in Managing EDS and Cataplexy
The demand for stimulants and selective serotonin to manage narcolepsy will dominate the global narcolepsy drugs market. Sodium oxybate, selective serotonin, is expected to lead the way. Its dual-pronged approach in treating EDS and cataplexy are driving the growth of this drug segment. According to Narcolepsy UK, it is only licensed to UCB Pharma Ltd., in Europe. Retailed under the name Xyrem, its demand is expected to hold a market share of 52% in 2021. It remains an FDA-approved treatment for cataplexy and is best known to allow patients to have an improved lifestyle whilst living with the neurological disorder.
Developed Regions Lead While Young Demographics of Asia Pacific Offers Lucrative Opportunities
Presently, the global narcolepsy drugs market is dominated by developed regions such as Europe and North America. Improved awareness, better medical care infrastructure, and higher healthcare infrastructure will allow Europe and North America to stay ahead of other regions. The recent outbreak of the COVID-19 pandemic has highlighted the issues of sleep disorder, which is also seen as an undercurrent to the demand for narcolepsy drugs. The North America narcolepsy drugs market is expected to showcase a CAGR of 11.3% between 2021 and 2026.
Meanwhile, Asia Pacific will prove to be a lucrative ground for narcolepsy drugs over the forecast period. Growing stress levels, sleep disorders due to shift-based work timings, and higher reach of medical awareness have prompted an interest in this disorder. As the younger demographic finds itself battling sleep issues, it is expected to highlight the often missed out narcolepsy in young patients. Populous economies such as India, China, and Japan are expected to be thriving markets for narcolepsy drugs between the forecast years of 2021 and 2025.
Some of the key players operating in the global narcolepsy drugs market are Addrenex Pharmaceuticals, Ligand Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Shire Plc, Arena Pharmaceuticals, Bioprojet, Jazz Pharmaceuticals Plc., and Graymark Healthcare, Inc.
Key Topics Covered:
1. Executive Summary
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Market Drivers
2.2.2. Market Restraints
2.2.3. Market Opportunities
2.3. Narcolepsy Drugs Pipeline Analysis
3. Global Narcolepsy Drugs Market Outlook, 2018 – 2026
3.1. Global Narcolepsy Drugs Market Outlook, By Therapeutics, 2018 – 2026
3.1.1. Key Highlights
3.1.2. Global Narcolepsy Drugs Market Outlook, by Therapeutics, Value (US$ Million), 2018 – 2026
3.1.2.1. Psychostimulants
3.1.2.2. Tricyclic Antidepressants
3.1.2.3. Sodium Oxybate
3.1.2.4. Selective Serotonin Reuptake Inhibitors
3.1.2.5. Others
3.1.3. Global Narcolepsy Drugs Market Share and BPS Analysis, by Therapeutics, 2021 and 2026
3.1.4. Global Narcolepsy Drugs Market Attractiveness Analysis, by Therapeutics, 2021-2026
3.2. Global Narcolepsy Drugs Market Outlook, By Narcolepsy Type, 2018 – 2026
3.2.1. Key Highlights
3.2.2. Global Narcolepsy Drugs Market Outlook, by Narcolepsy Type, Value (US$ Million), 2018 – 2026
3.2.2.1. Cataplexy
3.2.2.2. Without Cataplexy
3.2.3. Global Narcolepsy Drugs Market Share and BPS Analysis, by Narcolepsy Type, 2021 and 2026
3.2.4. Global Narcolepsy Drugs Market Attractiveness Analysis, by Narcolepsy Type, 2021-2026
3.3. Global Narcolepsy Drugs Market Outlook, By Region, 2018 – 2026
3.3.1. Key Highlights
3.3.2. Global Narcolepsy Drugs Market Outlook, by Region, Value (US$ Million), 2018 – 2026
3.3.2.1. North America
3.3.2.2. Europe
3.3.2.3. Asia Pacific
3.3.2.4. Rest of World
3.3.3. Global Narcolepsy Drugs Market Share and BPS Analysis, by Region, 2021 and 2026
3.3.4. Global Narcolepsy Drugs Market Attractiveness Analysis, by Region, 2021-2026
4. North America Narcolepsy Drugs Market Outlook, 2018 – 2026
5. Europe Narcolepsy Drugs Market Outlook, 2018 – 2026
6. Asia Pacific Narcolepsy Drugs Market Outlook, 2018 – 2026
7. Rest of World Narcolepsy Drugs Market Outlook, 2018 – 2026
8. Competitive Landscape
8.1. Market Share Analysis, 2021
8.2. Company Profiles
8.2.1. Jazz Pharmaceuticals, Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product Pipeline
8.2.1.4. Recent Developments
8.2.2. Harmony Biosciences
8.2.3. Avadel Pharmaceuticals plc
8.2.4. Axsome Therapeutics, Inc.
8.2.5. Arena Pharmaceuticals, Inc.
8.2.6. Graymark Healthcare, Inc.
8.2.7. Teva Pharmaceutical Industries Ltd.
8.2.8. Shionogi Inc.
8.2.9. Ligand Pharmaceuticals, Inc.
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/16biub
The Fed, Washington, and earnings helped the S&P 500 soar after the pandemic. They’re behind its slide now.
Prominent market technician Ralph Acampora says the recent bout of market volatility has him uneasy and now he's forecasting a deeper drop in the market.
In this article, we will be taking a look at Morgan Stanley’s top 10 stock picks for 2022. To skip our detailed analysis on Morgan Stanley’s stock picks and their performance, you can go directly to see Morgan Stanley’s Top 5 Stock Picks for 2022. In the aftermath of the breakout of the coronavirus pandemic […]
The start-up battery maker for electric vehicles is exploring other options, and the market isn't impressed.
With every top coin suffering the brunt of the crash, here are the possible reasons as to why it happened and what you can expect next.
In this week’s second 2022 Roundtable installment, Giroux highlights six stocks that, to his mind, have been unfairly punished. Mario Gabelli: I’ve been talking about the Atlanta Braves for a while. You can invest in the Braves through Liberty Braves Group [ticker: BATRA], a tracking stock controlled by John Malone’s Liberty Media It trades for $28, and there are 60 million shares outstanding.
Bears are in control as the market correction deepens. Apple and Tesla earnings loom but the Fed meeting will be in focus.
While myriad investing strategies have been effective in making long-term investors richer, perhaps none has a greater track record than buying into dividend stocks. Back in 2013, J.P. Morgan Asset Management, a division of JPMorgan Chase, issued a report that compared the performance of publicly traded companies that initiated a dividend and grew their payouts to public companies that didn't pay a dividend between 1972 and 2012.
The U.S. is approaching the end of a 'superbubble,' potentially leading to the largest markdown of wealth in its history when pessimism returns to rule markets, according to legendary investor Jeremy Grantham.
This fintech has an incredible story to tell, if the meme stock traders would just get out of the way.
Yahoo Finance's Jennifer Schonberger discusses the outlook for cryptocurrency prices after the Fed released a white paper on central bank digital currencies.
(Bloomberg) — Shopify Inc. plunged by the most since March 2020 after a report that the Canadian e-commerce company terminated contracts with several warehouse and fulfillment partners.Most Read from BloombergCrypto Crash Erases More Than $1 Trillion in Market Value‘Lethal’ U.S. Military Aid Begins Arriving in UkraineBitcoin Has Lost Half Its Value Since Hitting Record HighBitcoin Chart Hints at Possible Floor for SlideNasdaq 100’s Unrelenting Declines Ring a Dot-Com Bust Alarm BellIts U.S.-tra
A stock market crash can be a scary experience for investors, but it can also be an excellent opportunity for those who are prepared.
Shares of Walt Disney (NYSE: DIS) fell by 6.9% on Friday following the release of Netflix's (NASDAQ: NFLX) fourth-quarter results. Netflix warned of slowing subscriber growth for its popular streaming service. The digital entertainment leader expects to add just 2.5 million subscribers in the first quarter.
LONDON (Reuters) -Shell officially changed its name on Friday, ditching "Royal Dutch", which has been part of its identity since 1907, following plans to scrap its dual share structure and move its head office from the Netherlands to Britain. The London and Amsterdam stock exchanges will reflect the name change on Jan. 25 while the New York Stock Exchange will follow on Jan. 31. The change will not affect share ownership and the A shares and B shares will remain unchanged for the time being, Shell said.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Pfizer Inc…
Alphabet (NASDAQ:GOOG.L) has had a rough month with its share price down 11%. But if you pay close attention, you might…
Every fisherman knows that there’s good eating to be found on the seafloor and river bottoms. Flounder, halibut, sole, catfish – bottom dwellers are known for their good taste. And sometimes, the same can be said in the stock market. Share prices can fall for a wide range of reasons, and the market’s bottom fishers take advantage of that. The key is to find the best tasting morsels – those stocks that are priced low, but undervalued, and are not falling due to some fundamental flaw. There are pl
Netflix shares plunged after a disappointing quarter, but analysts insists there's no reason to panic.
After a difficult few months for the stock, SoFi (NASDAQ: SOFI) shareholders got some welcome news recently when regulators approved the company's application to become a bank. Now, SoFi will be able to complete its previously announced acquisition of Golden Pacific Bancorp and become a bank holding company. Following the news of the bank charter, SoFi's stock shot up.